1
/
of
1
Temotero (Temozolomide)
Temotero (Temozolomide)
Regular price
₱7,800.00 PHP
Regular price
Sale price
₱7,800.00 PHP
Unit price
₱1,560.00 each
Taxes included.
Quantity
Couldn't load pickup availability
Temozolomide (Temotero) is a potent chemotherapy medication specifically designed to treat primary brain cancers, including glioblastoma multiforme (GBM) and anaplastic astrocytoma. As an antineoplastic agent, temozolomide works by targeting and damaging cancer cell DNA, effectively halting tumor growth and enabling the body's natural elimination processes. This prescription medication is indicated for both newly diagnosed brain tumors and recurrent or progressive disease, frequently administered in combination with radiotherapy followed by maintenance monotherapy to optimize therapeutic outcomes.
Temozolomide belongs to the alkylating agent class of chemotherapy drugs and is particularly effective in crossing the blood-brain barrier, making it an essential treatment option for patients with glioblastoma multiforme when combined with concurrent radiation therapy. For anaplastic astrocytoma patients with recurrent or progressive tumors, temozolomide offers a reliable therapeutic pathway. Oncologists may also consider off-label applications in other malignancies based on individual patient circumstances and clinical judgment.
The medication requires careful patient selection and monitoring. Critical contraindications include documented hypersensitivity to temozolomide or dacarbazine (DTIC), as well as severe myelosuppression. Patients with hepatic dysfunction require cautious use with appropriate dose adjustments. Temozolomide is contraindicated during pregnancy and breastfeeding due to teratogenic potential and risks to fetal development.
Dosage administration is highly individualized and depends entirely on your oncologist's prescription and clinical assessment of your specific condition, tumor characteristics, and overall health status. Never initiate or modify temozolomide therapy without direct medical consultation and ongoing supervision by a qualified healthcare provider. Regular monitoring of blood counts and liver function is essential during treatment to manage potential adverse effects and ensure optimal therapeutic efficacy.
Temozolomide belongs to the alkylating agent class of chemotherapy drugs and is particularly effective in crossing the blood-brain barrier, making it an essential treatment option for patients with glioblastoma multiforme when combined with concurrent radiation therapy. For anaplastic astrocytoma patients with recurrent or progressive tumors, temozolomide offers a reliable therapeutic pathway. Oncologists may also consider off-label applications in other malignancies based on individual patient circumstances and clinical judgment.
The medication requires careful patient selection and monitoring. Critical contraindications include documented hypersensitivity to temozolomide or dacarbazine (DTIC), as well as severe myelosuppression. Patients with hepatic dysfunction require cautious use with appropriate dose adjustments. Temozolomide is contraindicated during pregnancy and breastfeeding due to teratogenic potential and risks to fetal development.
Dosage administration is highly individualized and depends entirely on your oncologist's prescription and clinical assessment of your specific condition, tumor characteristics, and overall health status. Never initiate or modify temozolomide therapy without direct medical consultation and ongoing supervision by a qualified healthcare provider. Regular monitoring of blood counts and liver function is essential during treatment to manage potential adverse effects and ensure optimal therapeutic efficacy.
Share
